The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.
The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.
Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.
Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
The diagnostics company said the number of tests accessioned during the quarter grew 60 percent year over year.
The test analyzes microRNA expression in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.
The test is used in conjunction with the firm's ThyGenX oncogene panel to assess fine needle aspiration samples from indeterminate thyroid nodules.
Researchers and clinicians attempting to select targeted therapies must take sample heterogeneity into account.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.